Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia of the European School of Hematology (ESH) took place on March 5-7, 2026, in Stockholm, Sweden. This meeting fostered scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide.
View all videos

ESH CLL 2026

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia
05–07 March 2026 | Stockholm, Sweden

ESH CLL 2026

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia
05–07 March 2026 | Stockholm, Sweden
The 4th Translational Research Conference: Chronic Lymphocytic Leukemia of the European School of Hematology (ESH) took place on March 5-7, 2026, in Stockholm, Sweden. This meeting fostered scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide.
View all videos

Latest Videos

View all
3:31
Epigenetic targeting and therapeutic potential of UVI5008 in CLL
Carmela Dell'Aversana • 13 Mar 2026
5:36
Positioning UVI5008 in treatment sequencing for CLL
Carmela Dell'Aversana • 13 Mar 2026
2:27
Epigenetic mechanisms and durability of response in CLL
Carmela Dell'Aversana • 13 Mar 2026
2:39
Therapy options after covalent BTK inhibitor failure in CLL
Gianluca Gaidano • 11 Mar 2026

BTK inhibitors

View all
2:45
Data supporting continuous BTKi therapy as SoC for patients with CLL
Kerry Rogers • 5 Mar 2026
1:40
Non-covalent BTK inhibitors in CLL: activity after covalent BTK inhibitors
Romain Guièze • 6 Mar 2026

BTK degraders

View all
2:19
Resistance to BTK degraders and combination strategies in CLL
Allison Cool • 6 Mar 2026
2:08
Future role of BTK degraders in CLL treatment
Justin Taylor • 6 Mar 2026

Venetoclax

View all
2:39
Therapy options after covalent BTK inhibitor failure in CLL
Gianluca Gaidano • 11 Mar 2026
1:20
Fixed-duration acalabrutinib combinations in CLL
Gianluca Gaidano • 11 Mar 2026

Immuno-Oncology

View all
5:36
Positioning UVI5008 in treatment sequencing for CLL
Carmela Dell'Aversana • 13 Mar 2026
2:27
Epigenetic mechanisms and durability of response in CLL
Carmela Dell'Aversana • 13 Mar 2026

Richter's transformation

View all
2:45
Genomic drivers and evolution of Richter’s transformation in CLL
Ferran Nadeu • 6 Mar 2026
2:11
Consensus guidelines for diagnosis, prognosis & clinical trials in Richter’s transformation
Adam Kittai • 6 Mar 2026
1:58
Key biomarkers for risk stratification in CLL
Anne-Sophie Michallet • 5 Mar 2026
3:28
Clonal evolution and genetic drivers of progression in CLL
Romain Guièze • 6 Mar 2026
The content of VJHemOnc is intended for healthcare professionals